At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed May 7, 2026 at 16:01 ET
Xenon Pharmaceuticals reported Q1 2026 net loss of $102.3M ($1.17/share) vs $65.0M ($0.83/share) in Q1 2025, with zero revenue compared to $7.5M a year ago. The miss is overshadowed by positive Phase 3 X-TOLE2 data for azetukalner in focal onset seizures, with an NDA submission expected in Q3 2026 and a strong cash position of $1.34B funding operations into 2029.
- Phase 3 X-TOLE2 study met primary endpoint with placebo-adjusted median percent change in seizure frequency of -42.7% (25 mg dose), the highest ever observed in a pivotal FOS study.
- NDA submission for azetukalner in focal onset seizures planned for Q3 2026.
- Cash, cash equivalents and marketable securities of $1,339.6 million as of March 31, 2026, up from $586.0 million at year-end 2025.
- Net loss increased to $102.3 million in Q1 2026 from $65.0 million in Q1 2025, driven by higher R&D spend and zero collaboration revenue.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access